Join the InvestorsHub Community

It was Dr. Dent who started NeoGenomics on its way with new ideas but as I said prior it was Douglas VanOort that put the company into orbit. I feel with H;LYK we have very little chance if any of the success that NeoGenomics had yet Dent said different a couple of years ago, hey what happened to that Dr. Dent? I feel we are too far behind everyone else and our technology seems not too forth coming meaning who wants it plus I don't need to address our patent again but do hope if Dr. Dent is seriously moving forward with more than a mom and pop business that is in retirement mode that he gains drastic help involving refining our patent in a huge way.

We see very little happening in the AI area as we had hoped so what gives? We can't move into any direction but no doubt that is what we may need to do. We see our share price at 4 cents again and it appears Dent/O'Leary must modify whatever plan of action/direction the company must move in within the next two months if not sooner.

Looks like someone had enough, nice volume thought!

Damn....grab your socks!

We have some news so what the heck at least we are still breathing

HealthLynked Achieves Key Milestone with Final $300,000 Payment from Sale of ACO Health Partners

NAPLES, Fla., Sept. 5, 2023 /PRNewswire/ -- HealthLynked Corp. (HLYK), a leader in the global healthcare network industry, is pleased to announce the successful completion of cash targets to date related to its January 2023 sale of ACO Health Partners ("AHP"). The company received a $300,000 payment, marking a 100% success rate in enrolling existing and new physician practices into Palm Beach Accountable Care Organization ("PBACO"), managed by PBACO Holding, LLC ("PBA").

Since the sale of AHP, HealthLynked has received a total of $3.25 million, comprised of an initial $750,000 from the sale and an additional $2.5 million in participation-based consideration. The payments represent the maximum amount of cash consideration to date that HealthLynked was eligible to receive under the sale agreement. The company is also expecting a further $500,000 in future savings in October 2024.

In line with the sale agreement, HealthLynked is set to receive net proceeds, including allocation of expenses, from Medicare Shared Savings attributed to AHP's performance in 2022. Current projections estimate these proceeds will exceed $1.0 million, with payments anticipated in early October 2023.

Furthermore, HealthLynked has secured a six-month extension from PBA for the possibility of earning equity in the event of PBA's future initial public offering ("IPO"). Initially slated to be completed by August 1, 2024, the deadline has been extended until February 1, 2025. Should PBA go public, HealthLynked will receive shares corresponding to AHP's 2021 earnings, times the EBITDA multiple used to value PBA's IPO shares.

George O'Leary, HealthLynked's Chief Financial Officer, commented, "Our collaboration with Palm Beach ACO has been outstanding, and we are excited about the prospects of continuing this successful partnership for years to come."

About HealthLynked

HealthLynked Corp. is revolutionizing healthcare by bridging the gap between patients and providers through its innovative, cloud-based platform. The HealthLynked Network aims to improve healthcare outcomes by facilitating the seamless exchange of medical information, empowering patients to take control of their healthcare journey.

For Patients: Free of charge, members can store vital medical information such as medications, allergies, past surgeries, and personal health records in one secure, online location. The platform allows easy connection with healthcare providers, both current and future, to ensure a more coordinated healthcare experience.

For Providers: Providers can join the network to gain access to HealthLynked's patented patient access hub, known as "PAH," which offers valuable patient analytics. The system also includes a suite of marketing tools designed to improve patient retention and facilitate better communication. Providers benefit from streamlined online appointment scheduling and can even fill last-minute cancellations using the platform's real-time appointment scheduling feature.

Membership and Costs

For Patients: Patients can sign up for HealthLynked at no cost, but upgraded services are only available to paid members. Free membership does not include advanced features such as access to HealthLynked's medical record management team, patient scheduling, and nurse onboarding services.

For Providers: Doctors and practices can claim their profile for free, allowing basic presence within the HealthLynked Network. Free profiles do not include access to premium services such as marketing tools, preferred placement within the network, patient record sharing, and other cost-saving features.

For Premium Members: Preferred providers can access HealthLynked's full range of services by paying a monthly fee, which includes marketing tools, priority placement within the network, and enhanced patient engagement features.

To learn more about how HealthLynked is changing the healthcare landscape, visit www.healthlynked.com. Stay connected with us on Twitter, Facebook, Instagram, and LinkedIn.

https://ih.advfn.com/stock-market/USOTC/healthlynked-qb-HLYK/stock-news/91965131/healthlynked-achieves-key-milestone-with-final-30

Yes, we look pretty bleak to say the least...just a mom and pop business so it appears Dr. Dent is in retirement mode.

HealthLynked Announces Steady YoY Revenue Increase for Q2 & H1 2023, Highlighting Significant Net Income Boost

Naples, Fla. -- August 15, 2023 -- InvestorsHub NewsWire -- HealthLynked Corp. (OTCQB: HLYK), a leading online healthcare network connecting patients, doctors, and medical data, provides an integrated platform designed for real-time collaboration and data exchange. At the heart of this is their patient-centric electronic medical record network, underscoring the pivotal role of patient engagement in healthcare decisions. Committed to redefining healthcare delivery, HealthLynked focuses on superior efficiency, precision, and affordability. Today, the company announced its financial reporting for the second quarter and first half ending June 30, 2023.


Q2 2023 Highlights:

Revenue: 9% YoY growth, reaching $1.70 million, up from Q2 2022's $1.56 million.

Primary Drivers of Revenue Growth: A notable 13% YoY increment from Functional Medicine offerings, complemented by contributions from Aesthetics Treatment Centers (acquired in May 2022).

Operating Loss Reduction: A remarkable 48% drop, moving from Q2 2022's $1.53 million to a more streamlined $0.80 million in 2023. This achievement is attributed to a blend of revenue augmentation and a targeted 34% YoY decrease in selling, general, and administrative expenses.

Net Loss Reduction: 37% decrease, tapering the net loss from $1.59M to $1.00M.

H1 2023 Highlights:

Revenue: 12% YoY increase, coming in at $3.46 million, compared to H1 2022's $3.09 million.

Operational Losses: Trimmed by 38%, declining from H1 2022's $2.98 million to $1.85 million in H1 2023, reflecting the combined impact of the 12% revenue growth and a 25% YoY cut in operational expenses.

Special Recognition: A gain of $2.67 million was recognized related to the divestiture of ACO Health Partners in January 2023.

Net Income: Net income of $0.45 million was reported, a positive shift from the net loss of $2.76 million observed in H1 2022, driven by the gain from the sale of ACO Health Partners coupled with revenue and cost improvements.

CEO, Dr. Michael Dent, expressed, "Our dedication to transforming the healthcare landscape remains unwavering. With a keen focus on streamlining operational efficiencies and nurturing consistent revenue growth, we've forged significant milestones in fortifying our financial trajectory. The inauguration of our premium offerings for patient members doesn't just broaden our service spectrum; it amplifies the essence of value we offer to our community. Central to this evolution has been the establishment of strategic alliances, each reinforcing our enduring mission: to deliver unparalleled healthcare at an affordable price point. Every initiative, every endeavor underscores our encompassing vision – to redefine and democratize quality healthcare, making 'better healthcare for less' a tangible reality for all."

George O'Leary, HealthLynked's Chief Financial Officer, added, "From a revenue perspective, we continue our strong quarterly and year to date revenue growth. We continue to strengthen our collaborative ties with Palm Beach ACO. Lastly, our year-to-date net income of $0.45 million compared to a net loss of $2.76 million in the previous year speaks to the work we have been doing to create more shareholder value."

About HealthLynked

HealthLynked Corp. provides a solution for both patient members and providers to improve healthcare through the efficient exchange of medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take more control of their healthcare. Members enter their medical information, including medications, allergies, past surgeries, and personal health records, in one convenient online and secure location, free of charge. Participating healthcare providers can connect with their current and future patients through the system. Benefits to in-network providers include the ability to utilize the HealthLynked patent-pending patient access hub "PAH" for patient analytics. Other benefits for preferred providers include HLYK marketing tools to connect with their active and inactive patients to improve patient retention, access more accurate and current patient information, provide more efficient online scheduling, and to fill last-minute cancelations using the Company's "real-time appointment scheduling" all within its mobile application. Preferred providers pay a monthly fee to access these HealthLynked services. For additional information about HealthLynked Corp., please visit www.healthlynked.com and connect with HealthLynked on Twitter, Facebook, Instagram, and LinkedIn.



Forward-Looking Statements & Risk Factors

Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results, including as a result of any acquisitions, performance, or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by our management, and us are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Certain risks and uncertainties applicable to our operations and us are described in the "Risk Factors" section of our most recent Annual Report on Form 10-K and in other filings we have made with the U.S. Securities and Exchange Commission. These reports are publicly available at www.sec.gov.

HLYK Contact:
Mike Paisan
Director of Investor Relations

IR@healthlynked.com

+1 (800)-928-7144, ext. 123

Well, whatever Dent is thinking he's certainly not communicating it to his shareholders, all 26 of us.

Probably but timing issues among other thoughts seem to happen. As for our darling Sabrina she would only be good to possibly help jump start HLYK since I view her as self serving, far too young to be satisfied very long without moving into being the star of everything but who knows what Dent is thinking?

Regurgitated from a low level postion in house,replaces equally wothless Sabrina Katz to trailblaze new paths fwd for HL.

I missed this PR back on 8/1/23

HealthLynked Corp. Names Wall Street Veteran Mike Paisan to Strategic Investor Relations Role


NAPLES, FL -- August 1, 2023 -- InvestorsHub NewsWire -- HealthLynked Corp. (HLYK), a global healthcare network specializing in care management for its members, announced the appointment of Mike Paisan as Director of Investor Relations and Strategic Partnerships. HealthLynked, which employs innovative healthcare technologies to link patients, doctors, and medical data, is committed to enhancing healthcare services worldwide.

In this new role, Mike will act as a dedicated liaison between the company and its investors, providing regular updates about the company's progress, answering shareholder queries, and keeping shareholders informed about the transformative work HealthLynked is doing in the healthcare sector through its technology.

As part of improving investor relations, Mike will also implement a series of enhancements, including updating the investor website for better accessibility and user experience.

Mike joined HealthLynked as a Business Analyst in September 2021, and his extensive research has played a pivotal role in the company's strategic decisions. As an expert in competitor analysis and industry trends, Mike has equipped HealthLynked with crucial insights for informed decision-making.

CEO Dr. Michael Dent commented, "Working with Mike has been a great experience. His in-depth research and understanding of the industry have helped us make more informed business decisions. It was a natural fit for Mike to take on the investor relations role as we continue to grow, and we are confident he will excel in this new position."

Mike's 20-year stint on Wall Street as a Sell-Side Equity Research Analyst has equipped him with invaluable expertise. His focus on large, publicly traded insurance companies, and his recognition by the Wall Street Journal as the “Best on the Street” analyst three times, attest to his analytical prowess.

https://www.prnewswire.com/news-releases/healthlynked-corp-names-wall-street-veteran-mike-paisan-to-strategic-investor-relations-role-301889633.html

I believe my average is higher not sure but do know it is because I would buy and sell this in order to gain more shares. We have experienced management which is good. My friends did warn me about Dent trying to break into the medicare area as it is super hard to stay alive being such a small company. As I said prior Dent has used his private companies doing the same hop scotch game and that is fine if it works for us shareholders. In any event dent protected himself as he will end up with the starting deck of cards one way or another. I still have hope but for something good to happen here and feel if nothing more we will exist as owning Dents medical operations and paying him and O' Leary as we just exist.

I wonder if Dan is still on board?

If we can't find (at least in my thinking) a new direction with a decent plan all the past puffing we all had seen involving Dr. Dent accomplishments will fade away into the sunset.

You gotta omit that having Dent/O"Leary is a damn good start but as for accomplishing what HealthLynked was to be I doubt....we need a new direction but how is that even possible with our backs pinned to the wall at least it seems that way!!

At this point i have written it off as another poor choice with an OTC and i certainlty should know better by now. That being said, it makes little sense to flush and there is that small % that they are just re inventing them selves and are coming up with an answer to profitability. Just can't see these two as typical snake oil CEO mgmt, they would have ripped the band aid off long ago and shuttered the biz. My average is.29 and it wouldn't take an earth shattering catalyst to get there,if only for a brief moment. You have to remember this thing has been off the radar for at least two years and there are very few shareholders..some new blood coming in and you just might be able to sell them your tickets.

If HLYK fails Dr. Dent doesn't just us shareholders along with HealthLynked Corporation. Dr. Dent covered his a$$ with massive millions of shares and you can't blame him I would do the same. The hope of AI was what he pushed and that doesn't look good. As for the patent that is so poorly written and I have no doubt that Dr. Dent knows this too. I should not talk about this area for a few reasons so I'll just clamp it about that.

Dr. Dent is good with ideas but not so much like involving NEO. Doug made that corporation fly.but I had high hope that Dr. Dent could make HLYK successful because it isn't a huge corporation yet allowing him to grow with the company. As for NEO Dent took the share price to $1.40-$1.60 as I recall and that is all.

I was so sadden when I did my in depth studies at the USPTO involving our patent.

Dr. Dent as most know here is to reward O'Leary for deals that he comes up with and those words kinda struck me like what is Dr. Dent doing is he just doing his medical practice and that other business from within his home or am I wrong?

I haven't checked to see if any new businesses have been initiated by Dr. Dent or O'Leary but will check in the next few days.

Lets hope they pull something out of their hat worth talking about. I do know Dr. Dent doesn't panic easily and works at his own speed so maybe all this will eventually work out for but short and long term traders and investors?

We will see what has been happening when they file their 10-Q in August.

So, does this company really have nothing? Spinning previous announcements that haven't fooled anybody.

I continue to watch large quantities of stock, 100K lots, trade at these low prices. I get it that someone is buying these but who is selling these? I can't imagine whoever is selling is any where close to breaking even.

Hell, I wanted to unload my position at $.20. Now I wonder if this ever sees $.10 again. Like I said before, I've been involved in two of these "Can't miss" OTC stocks, guess what...they both missed.

Sure looks like O' Leary is beating the same basic news releases? .... Damn shame!

Do you guys see that Form 4? Is that stating that George is now buying warrants for a past loan? It actually sounds as if the loan transaction/warrant purchase was a few days ago? It sounds ...but yet these warrants "to" be purchased but has not transpired yet?...my thoughts also think we will see another filing from Dent in the same manner?

I just hope this isn't a new loan?

Sounds like a great place to work lol

This is an "Indeed" review but don't know if it is a true?

Currently work here and how they treat the staff is disgusting 
  
 App analyst (Current Employee) - Naples - May 4, 2023 Indeed Featured review 
  
 The management and turnover is appalling. Too many managers. I’ve never felt 
 more unstable in a job. No perks to working here. They treat us like a number.  
 All they see are dollar signs and the CEO and CFO are never on the same page.  
 The app doesn’t work and they try to trick people into using it. They say a  
 nurse is answering the app questions but it’s really someone with no medical  
 background. The place is spiraling and a complete disaster. I am currently  
 looking for a new job. 
  
 Pros - None. My coworkers are the only pro. 
 Cons - Too many managers. Micromanaged to the core.

Here's the one good thing. A.I. is the hottest buzzword on Wall St,Dent was pimping it when noone else was, at least in the med records field. Pretty much everyone that was in this two years ago has moved on,it's back to 2018 valuations( ask me how i know) IF they release just the right PR with a sprinkling of A.I. pixie dust, you may have a chance to sell this bag of poop on a spike to the next OTC dreamer , be ready with that sell button..

Certainly I can. Their CFO publicly stated in their 10Q's that they were going to uplist. For 6 months this was listed in their 10Q's and suddenly it wasn't.

Look, all OTC stocks are risky and shit, for lack of a better word. The company's that play the kind of game Healthlynk did, are the worst because they string you along with the carrot.

I don't know Dr. Dent from desk chair. He's not looking real smart to me right now and those who did private placements in the $.50 range and above, based on the nonsense George Forman posted about uplisting, make them look real scammy to me.

Then that did that horrible S-1 with Yorkton.

I was hoping to get to .20 and take my loss, now I don't know how this gets back to $.10.

Then why bother with any PR's of late/ Not like they are doing anythIng for the SP.

Several years back Dr. Dent tried to build a multi-faceted medical business and failed but this time it looks like HLYK will pay the price and Dr. Dent will just continue his medical business with his wife and a few others. You can't blame him for this type of structure in business.

Sure looks like the game is over here. More and more 6 figure trades at lower prices. Either dilution or many folks are throwing in the towel. What a piece of shit.

They filed an 10-Q yesterday but I'm not through reading it. Did see where we are concerned about Russia and Ukraine war and also COVID. I sure hope O'Leary and Dent aren't trying to blame that for our poor business performance.

...back to reading the 10-Q

Where is this "shareholder value" they mentioned back in the 10K? Can't be many winners selling at these prices right now. JMO

The liabilities of everything fall on HLYK not Dr. Dent. If we fall he will end up doing as he did prior HLYK. Remember the shares he owns in HLYK. If you look at NeoGenomic Corporation you can see how Dent uses his medical practices. Also Dr. Dent has been trying to do what we see in HLYK for many years and you can see this if you look here.... https://dos.myflorida.com/sunbiz/

Now I'm in this as you are but it seems to me Dr. Dent must pull a rabbit out of his hat to make this work meaning a different avenue within the medical field. What happen to the so called AI talk? Now as for our patent it is better than nothing but not worth much in it's present form and definitions.

I have faith as you do that Dr. Dent will move in another direction but know I fear a RS when looking at what Dr. Dent had to do with Neo in the early early days.

Now this doesn't matter but while Dr. Dent was at the helm of what we know as NeoGenomic the stock price kissed $1.40 or a bit higher and that was all. Dr. Dent had multi millions of shares to maintain being in control, a powerful director but it was CEO - Douglas M. VanOort that moved the company in a huge way.

Now O' Leary is the one that is doing the foot work in trying to do what he can to move HLYK.

Dent is worth tens of miliions and has a medical practice, he can't be making more than peanuts if even that off HL,got to be in it to win it. I would like to think there is more afoot here than we know , and at .08 i'm stuck anyway so that's the story i'm stickin to.

You can look at this another way...Dr. Dent and O'Leary have a typical revenue stream that pays them in one fashion or another but as for us shareholders? We are holders of what is in the bag.

A generic medicine is required to be the same as a brand-name medicine in dosage, safety, effectiveness, strength, stability, and quality, as well as in the way it is taken.

I think you might be mistaken..

I did check the website extensively and no doubt Major has a huge reach but I never have liked generic drugs and yes many insurance payers insist generic products period.

Those products are among the cheapest versions. They are non branded so the price is really cheap. Generics are suppose to be within a tolerance level close to name brand so one of the aspirins could be 100mg another out of the bottle could be 125mg or 75mg. But overall the product will give an average of 100mg.

Dr. Dent...look I have no clue about what corporations buy medical stuff from us but look at these products? Do they look worth purchasing? I'm not trying to bad mouth us but I don't know if I would trust some of these items from the way the pictures look? Maybe in a 3rd world country and perhaps people might purchase the cheapest stuff available but I'm shaking my head at viewing some of these items?
https://www.medofficedirect.com/catalog/category/view/s/new-products/id/3/?manufacturer=141

Proactive link........ HLYK

<yt>NcrxeOkGtpc</yt>

Let me just say if I were that company that had anything to do with the wording or rewording the Inventors words as in/for Dr. Dent, the patent writer I would be extremely embarrassed if that is the case. Dr. Dent used probably one of the biggest companies in the world to handle that patent. Do you recall me stating a couple years ago that a patent can be provisional up to 1 year but by that time if not completed it would fall. There are slight exceptions to extend but not generally. What happen was when Dent initiated the start/paperwork of that patent he worked on it the first 6 days then nothing and it was booted out after the year however, they refiled. We need not talk any events past this point except we have the ability to use the patent as worded. Also we don't want to tough on patenability either, but by all means how in the world can Dr. Dent and O' Leary move into a new direction that would attract large shareholders not us retail holders.

I view Dr. Dent like this...he is very close with the NWC and all those professionals and will do what he can to protect them but us retail investors are a dime a dozen and can come and go in a flash to try and make a quick dollar. He works with these professionals he never sees any of us so all bets are off for him to salvage the "HealthLynked" part of the business.

______________________________________________________

Sometime people tend to think if a company goes private that that is good for investors that is so far from the truth. Now anyone who reads this I am just making this statement and it does not apply or am I implying that HLYK would go private.

They don't make any money, patent development burns cash. Positives are still to my knowledge principals haven't sold a single share and the mgmt team has remained intact. It always was a longshot, nothings changed there. Dent investing more cash in to his baby here would do wonders for the SP, AND a glympse in to their action plan wouldn't hurt either. We will probably get neither. This has become one that i forget about, but still has the ability to impress to the upside, certainly can't go much lower.

As it stands HLYK is not sitting in a comfortable chair meaning all us retail shareholders. I do know we have a present cap of 500 million authorized shares and presently as of 3/30./23 we were at 259 million OS however to cover various options and things like warrants that aspect will take roughly 93.5 million common shares that will eventually call for 352.6 million OS leaving roughly 147.3 million shares to work with. Now O' Leary might possibly allow 100 million shares of the 147.3 be used in some manner but with say 47.3 shares remaining will either call for a RS and or increasing the AS to around 750 Million..

The recent Patent, the patent is at least an effort to try and use the original PAH (hardware) Idea but as I see that at present will need refining and that I don't see happening anytime soon simply because money is going to get tight much quicker now without previous income.

HLYK was forced to let part of the business go and that is seen simply by looking at the various wordings within that sale. Maybe we were headed to a merger with these guys as we had hope prior but just didn't work out, who knows but if that money/merger deal with that company that could possibly IPO then that money could support us or at least give us some breathing room.

Do know if we fail that it is my opinion that Dr. Dent will end up doing what he does best at and for the "Woman's Center in Naples".

I see HLYK continually changing as we go and we must. Things...or some are just not working but regardless and we may not be successful we at least have a management team meaning O' Leary who is trying to make the numbers work and without him staying ahead of the game and out of as much danger financially or at least doing the financial structure in reporting as he has this no doubt would be called a scam by many but if each one of us as myself too (in which case) I have, read the SEC filings they are clear and straight forward.

We need a player with money that also has a new medical direction, probably a private company that may have poor management but needs a public traded corporation and someone to run it like Dr. Dent and O' Leary. Might be a high order but we can not (in my opinion) survive in the direction we are headed and the clock counting down.

As much as someone might need us is as much as we need them....simple said.

There ain't no "I" in Patent, but they iz in patient;) Please give me a PR that get's this to .29 for my BE, i swear i will never play an OTC again.

I see the talk over on Yahoo and can't blame anyone for their feelings involving the patent and our share price. I don't know if people understand this patent is just the right to use it, it doesn't mean it is proven patentability and I personally believe it won't since the wording customer was substituted for patient just for starters. The reasoning is Dr. Dent definition of customer is the patient (device). Now it is a positive move that Dr. Dent did so don't think this patent is junk unless we don't see them build on this patent. Who knows this patent could be used for other businesses and not by a patient. One other word is ALL patents you see that are issued regardless doesn't mean they are patentable meaning if they are challenged the PTAB will end up dealing with it but also the Federal District Court may have the final say depending on the challenges and rules of each court meaning PTAB and District Courts are different depending.

I wonder if we were going to originally merge with PBACO, LLC I mean it has 9 entities within. Did Dr. Dent & O'Leary sell ACO Health Partners to PBACO because we had to have the money or were we originally going to merge with them but the ACO savings money that seem to be held back by the SSA signal our company we can't move into this area directly but if PBACO does do an IPO they will do the work and O,Leary will have his hand palm up with a smile saying place the money right here boys. At any rate there might be a good chance that PBACO might IPO or something as such especially with having 9 entities to manage.

Thanks for the heads up Loc..

Just need to keep releasing relevant news often..

That explains the uptick in volume just after 1 today

New Proactive interview today

<yt>_Fp-Hblp_-U?t=5</yt>

I don't know as I haven't been watching that close but when in the same circumstances involving this stock it would seem 100k order would control the day depending on when it is placed and potential volume or needs of traders. I think all of us do that when we get stingy...at least I do.

The accumulation? could be but I am not even thinking about that but volume does attract me.

Now as for the recent Patent it is nice to have but only words and drawings on paper. I don't need to open up this avenue still early days so we can enjoy.

.10 sure looks better than .08